Mortality prediction by Carotid Intimal Medial Thickness with a novel Life Table Statistical Model

Christopher M Rembold

doi:10.1101/2025.02.03.25321583

ABSTRACT

Carotid Intimal Medial Thickness (CIMT) is an ultrasound estimate of preclinical atherosclerosis. The Charlottesville CIMT trial entered 1470 subjects from 1995 to 2011 and assessed total mortality in 2024 with a mean 15-year follow-up. In those subjects who reported no smoking or coronary disease, Cox statistics revealed that the presence of plaque and 4^th quartile common, bulb and internal CIMT measurements predicted total mortality (compared to the 1^st quartile). Age-normalized CIMT quartiles were less predictive. The age of subjects in the 4^th quartile was 15 years higher than the 1^st quartile. To correct for different ages, a novel life table model was created to analyze clinical data from a cohort who entered a trial at varying ages. This life table model allowed inclusion of subjects lost to follow-up. With this life table model, age-normalized 4^th and 3^rd quartile common, bulb and internal CIMT predicted total mortality. These data show the utility of measuring CIMT to predict mortality and the benefit of the life table model. The output statistic of the life table model, Age Difference, is an easily understandable and relevant measure of effect size.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

this study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol was approved by the University of Virginia Human Investigation Committee (#10915).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes